Tian Qiu-Si, Zhang ChunMei, Bao Zhi-Jun, Pei ZhiGang
Department of Neurosurgery, 3201 Hospital of Xi'an Jiaotong University Health Science Center, HanZhong, ShaanXi, China.
Department of Pathology, Chongqing University Jiangjin Hospital, ChongQing, China.
PeerJ. 2024 Dec 9;12:e18579. doi: 10.7717/peerj.18579. eCollection 2024.
Cluster of differentiation 47 (CD47), a transmembrane protein, plays a critical role in regulating cellular functions and maintaining immune homeostasis. Its expression has been shown to influence cancer prognosis. In this study, we investigated the role of CD47 in tumor progression in colon adenocarcinoma (COAD) and evaluated its potential as a target for immunotherapy.
We analyzed surgical samples from 96 COAD patients. Immunohistochemical analysis was performed on 90 samples, while the remaining 6 were subjected to multiplex immunofluorescence. To explore the association between CD47 expression and clinicopathological characteristics, we integrated transcriptome data from The Cancer Genome Atlas and the Gene Expression Omnibus using R software. The Tumor Immune Estimation Resource and Kaplan-Meier plotter were utilized to assess the relationship between CD47 expression, patient prognosis, and immune infiltration. Furthermore, the single-cell Tumor Immune System Interaction Database was used to examine the correlation between CD47 expression and the tumor microenvironment (TME). All included patients gave oral and written informed consent. The study was approved by the Ethics Committee of 3201 Hospital (full name: Medical Ethics Committee of 3201 Hospital).
CD47 was found to be overexpressed in various tumors, including COAD. Higher CD47 expression was significantly associated with more advanced tumor stages, including TNM staging, T staging, and N staging ( < 0.05). A robust correlation was observed between CD47 expression and immune cell infiltration in COAD. Patients with elevated CD47 expression tended to have longer disease-free intervals, although this benefit was diminished in cases with high infiltration of M1 macrophages. The immunosuppressive function of CD47 primarily acted through the CD47/SIRP pathway. Additionally, distinct cellular compositions and distributions were identified between primary and metastatic COAD, underscoring the heterogeneity of the TME. CD47 also influenced the TME by modulating cytokine and cytokine receptor interactions.
CD47 represents a promising prognostic biomarker and a potential target for immunotherapy in COAD. These findings provide new insights into therapeutic strategies aimed at modulating the TME and improving patient outcomes.
分化簇47(CD47)是一种跨膜蛋白,在调节细胞功能和维持免疫稳态中起关键作用。其表达已被证明会影响癌症预后。在本研究中,我们调查了CD47在结肠腺癌(COAD)肿瘤进展中的作用,并评估了其作为免疫治疗靶点的潜力。
我们分析了96例COAD患者的手术样本。对90个样本进行了免疫组织化学分析,其余6个样本进行了多重免疫荧光分析。为了探索CD47表达与临床病理特征之间的关联,我们使用R软件整合了来自癌症基因组图谱和基因表达综合数据库的转录组数据。利用肿瘤免疫估计资源和Kaplan-Meier绘图工具评估CD47表达、患者预后和免疫浸润之间的关系。此外,使用单细胞肿瘤免疫系统相互作用数据库检查CD47表达与肿瘤微环境(TME)之间的相关性。所有纳入患者均给予口头和书面知情同意。本研究得到了3201医院伦理委员会(全称:3201医院医学伦理委员会)的批准。
发现CD47在包括COAD在内的各种肿瘤中过表达。较高的CD47表达与更晚期的肿瘤分期显著相关,包括TNM分期、T分期和N分期(<0.05)。观察到CD47表达与COAD中的免疫细胞浸润之间存在密切相关性。CD47表达升高的患者往往有更长的无病间期,尽管在M1巨噬细胞高浸润的病例中这种益处有所减弱。CD47的免疫抑制功能主要通过CD47/SIRP途径发挥作用。此外,在原发性和转移性COAD之间鉴定出不同的细胞组成和分布,突出了TME的异质性。CD47还通过调节细胞因子和细胞因子受体相互作用来影响TME。
CD47是COAD中有前景的预后生物标志物和免疫治疗的潜在靶点。这些发现为旨在调节TME和改善患者预后的治疗策略提供了新的见解。